Whole genome sequencing consortium on Frontotemporal dementia with underlying TDP-43 pathology

针对具有潜在 TDP-43 病理学的额颞叶痴呆的全基因组测序联盟

• 批准号: 9751999
• 负责人: Rosa Rademakers
• 金额: $ 122.78万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-25 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9751999
• 关键词: Advanced Development; Affect; Age; Alzheimer' s Disease; Applications Grants; Biochemical; Biochemistry; Biocompatible Materials; Bioinformatics; Biological Assay; Biological databases; Brain; Brain region; C9ORF72; CRISPR interference; CRISPR/Cas technology; Candidate Disease Gene; Cell model; Cells; Cerebrospinal Fluid; Cessation of life; Clinic; Clinical; Collaborations; Collection; Communication; Communities; DNA; Data; Data Set; Databases; Dementia; Dementia With Amyotrophic Lateral Sclerosis; Deposition; Diagnosis; Disease; Disease Progression; Family; Fibroblasts; Frontotemporal Dementia; Frontotemporal Lobar Degenerations; Functional disorder; Future; Genes; Genetic; Genetic Predisposition to Disease; Genomics; Goals; Grant; Homeostasis; Human; Image; International; Knowledge; Medical; Metabolism; Minority; Motor Neuron Disease; Mutation; Neurodegenerative Disorders; Neuroglia; Neurons; Nuclear; PGRN gene; Pathologic; Pathology; Pathway interactions; Patient Recruitments; Patients; Personality; Phase; Phenotype; Plasma; Pluripotent Stem Cells; Population; Positioning Attribute; Predisposition; Primary Progressive Aphasia; Process; Proteomics; Quality Control; RNA; Repression; Research; Research Personnel; Risk; Role; Sampling; Semantics; Site; Statistical Data Interpretation; Stem cells; Technology; Tissues; United States National Institutes of Health; Validation; Variant; biobank; biomarker development; brain tissue; cellular imaging; clinical Diagnosis; clinical subtypes; cloud based; cohort; database of Genotypes and Phenotypes; gain of function; genetic variant; genome sequencing; human stem cells; in vivo; induced pluripotent stem cell; innovation; insight; new therapeutic target; novel; patient subsets; phenotypic data; protein TDP-43; proteostasis; stressor; trafficking; transcriptomics; whole genome

This UG3/UH3 proposal aims to identify and functionally validate novel genes for frontotemporal lobar degeneration with underlying TDP-43 pathology (FTLD-TDP) through the establishment of an international Sequencing Consortium and an interdisciplinary team of investigators. FTLD comprises a genetically, clinically and pathologically heterogeneous collection of neurodegenerative diseases affecting the frontal and temporal brain regions. Its diagnosis can be challenging and no treatments to slow or stop disease progression exist, highlighting the enormous unmet medical need of FTLD patients. FTLD represents 10-20% of all dementias and is clinically important because of its earlier age at onset compared to Alzheimer's disease (AD) and its dramatic impact on core human qualities, including personality, insight and verbal communication. FTLD-TDP represents the most common FTLD pathological subtype and two major genes have previously been implicated in its genetic etiology, both identified by our study team: mutations in progranulin (GRN) and repeat expansions in the chromosome 9 open reading frame 72 (C9ORF72). However, despite these major advances the cause of the disease in more than 50% of FTLD-TDP patient remains unexplained and much of the pathophysiology underlying FTLD-TDP unknown. In the UG3 phase of this proposal, we will collect biospecimens and detailed phenotypic data from patients with pathologically confirmed FTLD-TDP and patients with clinical diagnoses of semantic variant primary progressive aphasia (svPPA) and frontotemporal dementia with amyotrophic lateral sclerosis (FTD/ALS), highly likely to have TDP-43 pathology from more than 30 sites world- wide (Aim 2). Whole genome sequencing (WGS) will be performed on 625 new FTLD patients and combined with publically available WGS data on 3000 controls to comprise a genetic replication cohort. In Aims 1a+b, WGS data from the replication cohort and a previously generated discovery cohort (500 FTLD-TDP patients and 1000 controls) will be processed through an analytical pipeline developed in collaboration with other FTD consortia. Statistical analyses will subsequently nominate candidate FTLD genes and variants. In the UH3 phase of this proposal, we will prioritize and validate candidate FTLD genes using integrative genomic, transcriptomic, proteomic and statistical analyses in vivo using tissues or cells isolated from FTLD-TDP patients and controls (Aim 3) and ex vivo using human induced pluripotent stem cell models using integrative transcriptomic, proteomic, and high- content imaging assays (Aim 4). Through the discovery of novel FTLD-TDP disease genes we will provide important novel insight into FTLD-TDP pathobiology, advance the development of biomarkers and provide novel targets for therapies.

这项UG3/UH3提案旨在通过建立一个国际测序联盟和一个跨学科的研究团队，鉴定和功能验证具有潜在TDP-43病理的额颞叶变性（FTLD-TDP）的新基因。FTLD包括影响额叶和颞叶脑区的遗传、临床和病理异质性的神经退行性疾病。它的诊断可能具有挑战性，并且没有减缓或阻止疾病进展的治疗方法，这突出了FTLD患者巨大的未满足的医疗需求。FTLD占所有痴呆症的10-20%，具有重要的临床意义，因为与阿尔茨海默病（AD）相比，FTLD发病年龄更早，并且对人格、洞察力和语言沟通等核心人类品质产生巨大影响。FTLD- tdp代表了最常见的FTLD病理亚型，两个主要基因先前与其遗传病因有关，这两个基因都是由我们的研究小组确定的：前颗粒蛋白（GRN）突变和9号染色体开放阅读框72 （C9ORF72）的重复扩增。然而，尽管取得了这些重大进展，但超过50%的FTLD-TDP患者的病因仍然不明，FTLD-TDP的许多病理生理机制尚不清楚。在本提案的UG3阶段，我们将收集来自全球30多个地点的病理证实的FTLD-TDP患者和临床诊断为语义变异型原发性进行性失语症（svPPA）和额颞叶痴呆合并肌萎缩侧索硬化症（FTD/ALS）的患者的生物标本和详细的表型数据，这些患者极有可能患有TDP-43病理（目的2）。将对625例新的FTLD患者进行全基因组测序（WGS），并结合3000名对照者的公开WGS数据，组成一个基因复制队列。在Aims 1a+b中，来自复制队列和先前生成的发现队列（500名FTLD-TDP患者和1000名对照）的WGS数据将通过与其他FTD联盟合作开发的分析管道进行处理。统计分析将随后提名候选FTLD基因和变异。在该提案的UH3阶段，我们将利用从FTLD- tdp患者和对照组分离的组织或细胞（Aim 3）进行体内整合基因组学、转录组学、蛋白质组学和统计分析，优先考虑和验证候选FTLD基因（Aim 4），并利用人类诱导多能干细胞模型（Aim 4）进行整合转录组学、蛋白质组学和高含量成像分析（Aim 4）。通过发现新的FTLD-TDP疾病基因，我们将为FTLD-TDP病理生物学提供重要的新见解，推动生物标志物的发展，并为治疗提供新的靶点。